RxDoctor Payments Data

Imad Haddad, MD

Internal Medicine · Springfield, KYNPI 1508880063

Payments from drug & device makers

$763in general payments, 2019–2025

Across 44 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$112
  • Exact Sciences$98
  • GSK$74
  • AbbVie$69
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$40
  • Johnson & Johnson$39
  • plus $330 from 15 others

What the payments were for

  • Food & beverage$763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$763 in reported general payments places this provider in the 60th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$13,577
Medicare patients
96
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$44,602
JanuviaSitagliptin Phosphate36$43,286
LinzessLinaclotide40$36,368
Breo ElliptaFluticasone/Vilanterol57$31,524
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$27,186
JardianceEmpagliflozin20$24,350
XareltoRivaroxaban26$20,194
OzempicSemaglutide19$19,998
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$19,594
ProliaDenosumab11$19,298
MounjaroTirzepatide13$13,660
SymbicortBudesonide/Formoterol Fumarate26$10,235
Atrovent HfaIpratropium Bromide15$8,973
InvokanaCanagliflozin11$8,715
Humalog Kwikpen U-100Insulin Lispro21$6,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$74$78,30499 claims
PfizerEliquis$28$44,60247 claims
MerckJanuvia$13$43,28636 claims
AbbVieLinzess$69$36,36840 claims
Johnson & JohnsonXarelto, Invokana$39$28,90837 claims
Novo NordiskOzempic$21$19,99819 claims
AmgenProlia$38$19,29811 claims
Lilly USA, LLCMounjaro$15$13,66013 claims
AstraZenecaSymbicort$13$10,23526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Springfield

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →